Lucas Ferrari de Andrade, PhD
- ASSISTANT PROFESSOR | Oncological Sciences
Research Topics:Cancer, Immunology
Dr. Ferrari de Andrade received his PhD in Cellular and Molecular Biology from Universidade Federal do Paraná, Brazil, in 2014. During this period, he also developed part of his Ph.D. for 12 months in the QIMR Berghofer Medical Research Institute, Australia. In 2014, right after obtaining his Ph.D., Dr. Ferrari de Andrade started his 5-years postdoctoral training in the Dana-Farber Cancer Institute / Harvard Medical School. In 2019, Dr. Ferrari de Andrade joined the Precision Immunology Institute in the Icahn School of Medicine at Mount Sinai, to start his own laboratory. Since then, his laboratory has been working to develop new immunotherapies for cancers.
Multi-Disciplinary Training AreasCancer Biology [CAB], Immunology [IMM]
BSc / Lic, Universidade Federal do Parana
MSc, Universidade Federal do Parana
PhD, Universidade Federal do Parana
Visiting Student, QIMR Berghofer Medical Research Institute
Postdoc, Dana-Farber Cancer Institute
Natural Killer Cells and Cancer Immunotherapy
Natural killer cells, as the name implies, are lymphocytes that kill aberrant cells such as the ones that undergo malignant transformation. However, cancers often develop because of, at least in parts, mechanisms of immune evasion. Our laboratory develops antibodies that restore the immune surveillance for transformed cells. We reason that such antibodies could serve as immunotherapeutics for a variety of cancers.
Visit the Ferrari de Andrade Laboratory
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ferrari de Andrade during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Dana-Farber Cancer Institute; Innate Pharma
- Fate Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.